[{"address1": "10955 Vista Sorrento Parkway", "address2": "Suite 200", "city": "San Diego", "state": "CA", "zip": "92130", "country": "United States", "phone": "858 751 4493", "website": "https://www.januxrx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients with cancer. Its clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. Janux Therapeutics, Inc. has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. The company was incorporated in 2017 and is headquartered in San Diego, California.", "fullTimeEmployees": 81, "companyOfficers": [{"maxAge": 1, "name": "Dr. David Alan Campbell Ph.D.", "age": 64, "title": "President, CEO & Director", "yearBorn": 1960, "fiscalYear": 2024, "totalPay": 1130500, "exercisedValue": 0, "unexercisedValue": 107640504}, {"maxAge": 1, "name": "Dr. Thomas  Diraimondo Ph.D.", "age": 37, "title": "Chief Scientific Officer", "yearBorn": 1987, "fiscalYear": 2024, "totalPay": 630000, "exercisedValue": 0, "unexercisedValue": 28001912}, {"maxAge": 1, "name": "Mr. Byron  Robinson J.D., Ph.D.", "age": 59, "title": "Chief Strategy Officer", "yearBorn": 1965, "fiscalYear": 2024, "totalPay": 727500, "exercisedValue": 0, "unexercisedValue": 7877545}, {"maxAge": 1, "name": "Mr. Matt  Whitmire", "title": "Vice President of Finance", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Maria  Dobek", "age": 34, "title": "Principal Accounting Officer & VP of Accounting", "yearBorn": 1990, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Charles M. Winter", "age": 54, "title": "Chief Technical Officer", "yearBorn": 1970, "fiscalYear": 2024, "totalPay": 590400, "exercisedValue": 0, "unexercisedValue": 460878}, {"maxAge": 1, "name": "Mr. James  Pennington", "title": "General Counsel & Corporate Secretary", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Andy Hollman Meyer", "age": 40, "title": "Chief Business Officer", "yearBorn": 1984, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Zachariah  McIver D.O., Ph.D.", "age": 54, "title": "Chief Medical Officer", "yearBorn": 1970, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 7, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1746057600, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 25.7, "open": 25.74, "dayLow": 24.13, "dayHigh": 26.87, "regularMarketPreviousClose": 25.7, "regularMarketOpen": 25.74, "regularMarketDayLow": 24.13, "regularMarketDayHigh": 26.87, "payoutRatio": 0.0, "beta": 3.239, "forwardPE": -16.50625, "volume": 827381, "regularMarketVolume": 827381, "averageVolume": 939824, "averageVolume10days": 1071550, "averageDailyVolume10Day": 1071550, "bid": 26.19, "ask": 26.63, "bidSize": 1, "askSize": 1, "marketCap": 1560965632, "fiftyTwoWeekLow": 22.52, "fiftyTwoWeekHigh": 71.71, "priceToSalesTrailing12Months": 147.42781, "fiftyDayAverage": 29.8136, "twoHundredDayAverage": 42.969673, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 516854272, "profitMargins": 0.0, "floatShares": 37412967, "sharesOutstanding": 59105100, "sharesShort": 9340605, "sharesShortPriorMonth": 10497950, "sharesShortPreviousMonthDate": 1741910400, "dateShortInterest": 1744675200, "sharesPercentSharesOut": 0.158, "heldPercentInsiders": 0.06587, "heldPercentInstitutions": 1.13738, "shortRatio": 9.26, "shortPercentOfFloat": 0.2802, "impliedSharesOutstanding": 59105100, "bookValue": 17.316, "priceToBook": 1.525179, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -68994000, "trailingEps": -1.28, "forwardEps": -1.6, "enterpriseToRevenue": 48.815, "enterpriseToEbitda": -5.34, "52WeekChange": -0.5051983, "SandP52WeekChange": 0.08001411, "quoteType": "EQUITY", "currentPrice": 26.41, "targetHighPrice": 200.0, "targetLowPrice": 41.0, "targetMeanPrice": 90.81818, "targetMedianPrice": 90.0, "recommendationMean": 1.23077, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 11, "totalCash": 1025172992, "totalCashPerShare": 17.345, "ebitda": -96787000, "totalDebt": 23025000, "quickRatio": 59.027, "currentRatio": 59.205, "totalRevenue": 10588000, "debtToEquity": 2.251, "revenuePerShare": 0.197, "returnOnAssets": -0.08569, "returnOnEquity": -0.100930005, "grossProfits": -57800000, "freeCashflow": -26144376, "operatingCashflow": -43814000, "revenueGrowth": -1.0, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -9.33576, "financialCurrency": "USD", "symbol": "JANX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "REGULAR", "shortName": "Janux Therapeutics, Inc.", "longName": "Janux Therapeutics, Inc.", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1623418200000, "regularMarketChange": 0.7099991, "regularMarketDayRange": "24.13 - 26.87", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 939824, "fiftyTwoWeekLowChange": 3.8899994, "fiftyTwoWeekLowChangePercent": 0.17273532, "fiftyTwoWeekRange": "22.52 - 71.71", "fiftyTwoWeekHighChange": -45.3, "fiftyTwoWeekHighChangePercent": -0.63171107, "fiftyTwoWeekChangePercent": -50.51983, "earningsTimestamp": 1740690060, "earningsTimestampStart": 1746734400, "earningsTimestampEnd": 1747166400, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -1.28, "epsForward": -1.6, "epsCurrentYear": -2.0775, "priceEpsCurrentYear": -12.712394, "fiftyDayAverageChange": -3.4036007, "fiftyDayAverageChangePercent": -0.11416268, "twoHundredDayAverageChange": -16.559673, "twoHundredDayAverageChangePercent": -0.38538048, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-06-11", "averageAnalystRating": "1.2 - Strong Buy", "cryptoTradeable": false, "corporateActions": [], "regularMarketTime": 1746724696, "exchange": "NGM", "messageBoardId": "finmb_676965261", "exchangeTimezoneName": "America/New_York", "regularMarketChangePercent": 2.7626424, "regularMarketPrice": 26.41, "displayName": "Janux Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-05-08"}]